Su Jeong Song1, Ji Min1, Sung Yun Suh1, Sun Hoi Jung1, Hyeon Joo Hahn1, Seock-Ah Im2, Ju-Yeun Lee3. 1. Department of Pharmacy, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. 2. Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea. 3. College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, 55 Hanyangdaehak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, South Korea. jypharm@hanyang.ac.kr.
Abstract
PURPOSE: Taxane-induced peripheral neuropathy (TIPN) can affect quality of life and treatment outcomes in breast cancer patients. Despite the high incidence, treatment of PN has not been established. This study aimed to evaluate the incidence, risk factors, and prescribing pattern of TIPN receiving pharmacologic treatment in real-world practice. METHODS: We conducted a retrospective chart review of 1629 breast cancer patients who received taxanes at the Seoul National University Hospital from July 2012 to June 2014. We determined the incidence and predictors for TIPN treated with anti-neuropathic pain medications during taxane treatment and the 1-year follow-up period after discontinuation of taxanes. The prescribing pattern of anti-neuropathic drugs was also analyzed. RESULTS: A total of 1516 patients with breast cancer were included, and the incidence of TIPN receiving treatment was 21.9% overall, with 42.2% of patients using paclitaxel and 15.8% using docetaxel. The median time to the first anti-neuropathic pain medication prescribed from the start of taxane treatment was 64 days and was significantly earlier in the paclitaxel group. In 21% of patients, TIPN treatment was started after the end of taxane treatment. Identified risk factors for TIPN were paclitaxel use (vs. docetaxel), old age, overweight, metastatic (vs. non-metastatic) breast cancer, and possibly a 3-weekly taxane schedule (vs. weekly). Gabapentin and pregabalin accounted for 71.7 and 24.3% of total use of anti-neuropathic agents, respectively. CONCLUSIONS: One-fifth of breast cancer patients who were treated with taxane-based chemotherapy experienced TIPN receiving treatment, and its risk factors were paclitaxel use, old age, overweight, and metastatic cancer.
PURPOSE:Taxane-induced peripheral neuropathy (TIPN) can affect quality of life and treatment outcomes in breast cancerpatients. Despite the high incidence, treatment of PN has not been established. This study aimed to evaluate the incidence, risk factors, and prescribing pattern of TIPN receiving pharmacologic treatment in real-world practice. METHODS: We conducted a retrospective chart review of 1629 breast cancerpatients who received taxanes at the Seoul National University Hospital from July 2012 to June 2014. We determined the incidence and predictors for TIPN treated with anti-neuropathic pain medications during taxane treatment and the 1-year follow-up period after discontinuation of taxanes. The prescribing pattern of anti-neuropathic drugs was also analyzed. RESULTS: A total of 1516 patients with breast cancer were included, and the incidence of TIPN receiving treatment was 21.9% overall, with 42.2% of patients using paclitaxel and 15.8% using docetaxel. The median time to the first anti-neuropathic pain medication prescribed from the start of taxane treatment was 64 days and was significantly earlier in the paclitaxel group. In 21% of patients, TIPN treatment was started after the end of taxane treatment. Identified risk factors for TIPN were paclitaxel use (vs. docetaxel), old age, overweight, metastatic (vs. non-metastatic) breast cancer, and possibly a 3-weekly taxane schedule (vs. weekly). Gabapentin and pregabalin accounted for 71.7 and 24.3% of total use of anti-neuropathic agents, respectively. CONCLUSIONS: One-fifth of breast cancerpatients who were treated with taxane-based chemotherapy experienced TIPN receiving treatment, and its risk factors were paclitaxel use, old age, overweight, and metastatic cancer.
Entities:
Keywords:
Breast cancer; Docetaxel; Paclitaxel; Peripheral neuropathy; Treatment
Authors: Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss Journal: Oncologist Date: 2018-12-14
Authors: Zhu Li; Carolyn A Meyers; Leslie Chang; Seungyong Lee; Zhi Li; Ryan Tomlinson; Ahmet Hoke; Thomas L Clemens; Aaron W James Journal: J Clin Invest Date: 2019-12-02 Impact factor: 14.808
Authors: Hannah C Timmins; David Mizrahi; Tiffany Li; Matthew C Kiernan; David Goldstein; Susanna B Park Journal: J Cancer Surviv Date: 2021-01-12 Impact factor: 4.442
Authors: Katrin A Becker; Anne-Kathrin Uerschels; Laura Goins; Suzanne Doolen; Kristen J McQuerry; Jacek Bielawski; Ulrich Sure; Erhard Bieberich; Bradley K Taylor; Erich Gulbins; Stefka D Spassieva Journal: J Neurochem Date: 2020-03-13 Impact factor: 5.372
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Rashi Asthana; Liying Zhang; Bo Angela Wan; Daniela Gallo-Hershberg; Angie Giotis; Mark Pasetka; Jenna van Draanen; Shannon Goodall; Patrick L Diaz; Leah Drost; Edward Chow; Carlo De Angelis Journal: Support Care Cancer Date: 2019-05-17 Impact factor: 3.603
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Hannah C Timmins; Tiffany Li; David Goldstein; Terry Trinh; David Mizrahi; Michelle Harrison; Lisa G Horvath; Michael Friedlander; Matthew C Kiernan; Susanna B Park Journal: J Cancer Surviv Date: 2021-02-27 Impact factor: 4.442
Authors: Alex J Fauer; Matthew A Davis; Sung Won Choi; Lauren P Wallner; Christopher R Friese Journal: Support Care Cancer Date: 2019-10-25 Impact factor: 3.603
Authors: Ilana Usiskin; Fangyong Li; Melinda L Irwin; Brenda Cartmel; Tara Sanft Journal: Breast Cancer Res Treat Date: 2020-10-30 Impact factor: 4.872